Metabolic activity by 18 F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC

Nivolumab, an anti-programmed death-1 (PD-1) antibody, is administered in patients with previously treated non-small cell lung cancer. However, little is known about the established biomarker predicting the efficacy of nivolumab. Here, we conducted a preliminary study to investigate whether F-FDG-PE...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of nuclear medicine and molecular imaging 2018-01, Vol.45 (1), p.56
Hauptverfasser:	Kaira, Kyoichi, Higuchi, Tetsuya, Naruse, Ichiro, Arisaka, Yukiko, Tokue, Azusa, Altan, Bolag, Suda, Satoshi, Mogi, Akira, Shimizu, Kimihiro, Sunaga, Noriaki, Hisada, Takeshi, Kitano, Shigehisa, Obinata, Hideru, Yokobori, Takehiko, Mori, Keita, Nishiyama, Masahiko, Tsushima, Yoshihito, Asao, Takayuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - diagnostic imaging Carcinoma, Non-Small-Cell Lung - drug therapy Female Fluorodeoxyglucose F18 Humans Lung Neoplasms - diagnostic imaging Lung Neoplasms - drug therapy Male Middle Aged Nivolumab Positron Emission Tomography Computed Tomography Predictive Value of Tests Radiopharmaceuticals
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!